Skip to main content

Table 3 High Scoring Pairs of Interest from TF Model

From: Predicting clinically promising therapeutic hypotheses using tensor factorization

Target

High Scoring Indication in Clinical Pipeline (Phase*)

PubmedID

Related Approved Indication (Total Approved Indications)

ABCC8

Glucose Intolerance (III)

23903354

Diabetes Mellitus (1)

ADRB1

Cachexia (II)

20426789

Ischemia (13)

ADRB2

Hypoglycemia (I)

22013013

Glaucoma (15)

ADRB2

Myocardial Infarction (III)

26692153

Heart Failure (15)

AGTR1

Hypercholesterolemia (III)

12117739

Hyperlipidemias (7)

CYP3A4

Hepatitis C (II)

20938912

HIV Infections (1)

IL2

Behcet Syndrome (II)

26654556

Graft Rejection (1)

IL6

Waldenstrom Macroglobulinemia (I)

26238488

Giant Lymph Node Hyperplasia (1)

IL6

Arthritis, Psoriatic (II)

27789987

Giant Lymph Node Hyperplasia (1)

OPRM1

Schizophrenia (III)

27397309

Migraine Disorders (22)

RYR1

Muscular Dystrophy, Duchenne (I)

26793121

Malignant Hyperthermia (1)

SERPINC1

Hemophilia (II)

27099538

Blood Coagulation Disorders (16)

TNFSF11

Hypercalcemia (II)

27904108

Osteoporosis (1)

VDR

Alopecia (I)

27932380

Keratosis (9)

VDR

Cachexia (I)

22497530

Chronic Kidney Failure (9)

  1. New indications of approved targets in clinical trials (Phase* as of May 27, 2016) that have the highest probability of eventual clinical success as measured by the tensor factorization model. The full list is available in the supplement. For illustrative purposes, we list a related indication approved for assets for each target